POU4F3 and endometrial cancer: Previous studies utilizing methylation assays of CDO1 and BHLHE22 coupled with age and BMI in 494 patients [5], POU4F3/MAGI2 in 30 patients [21], and ZSCAN12/GYPC in 399 patients [16] found a sensitivity of 92.5%, 83–90%, and 90.9%, respectively, and a specificity of 73.8%, 69–75%, and 92.1%, respectively, for endometrial cancer detection.